Gout pill could be prime candidate to treat seriously ill COVID-19 patients says new study
THE UNPRECEDENTED scale of the vaccine rollout has proven an effective shield against infection. For those who do become infected and become seriously ill, however, current go-to treatments are massively limited. One new study has suggested the gout drug remdesivir could be a prime candidate to treat severely ill COVID-19 patients.
This article summarizes the top 20 research studies of 2020 identified as POEMs (patient-oriented evidence that matters), including the two most highly rated guidelines of the year on gout and chronic obstructive pulmonary disease (COPD). Regarding COVID-19, handwashing and social distancing through stay-at-home orders or quarantine measures are effective at slowing the spread of illness. Use of proper face masks (not gaiters or bandanas) is also effective at preventing trans- mission. This is important because the virus can infect others during the presymptomatic phase. Aspirin can no longer be recommended for the primary...
CONCLUSION: The data collected does not support the concern for an increased risk of developing adverse reactions following soft tissue filler injections associated with the COVID-19 vaccines compared to that risk associated with other previously described triggers or the default risk following soft tissue filler injections. J Drugs Dermatol. 20(4):374-378. doi:10.36849/JDD.2021.6041.PMID:33852237 | DOI:10.36849/JDD.2021.6041